Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma

Kobayashi, Hiroshi; Okuma, Tomotake; Oka, Hiroyuki; Okajima, Koichi; Ishibashi, Yutaka; Zhang, Liuzhe; Ohki, Takahiro; Tsuda, Yusuke; Ikegami, Masachika; Sawada, Renshi; Shinoda, Yusuke; Akiyama, Takahiro; Kawano, Hirotaka; Goto, Takahiro; Tanaka, Sakae

doi:10.1007/s10147-018-1370-8

Cited by 11 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many cancer types, grade 3/4 neutropenia is associated with increased survival. 19 Although neutropenia during chemotherapy could be influenced by the pretreatment neutrophil count, 20 as shown in our cases, this result indicates that Cancer March 15, 2020 sufficient drug exposure is important to gain clinical benefits. However, grade 3 neutropenia was not associated with better OS, and we did not evaluate the quality of life.…”

Section: Discussionmentioning

confidence: 51%

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

Kobayashi

Iwata

Wakamatsu

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

Background Although initial trabectedin (1.2 mg/m2) is safe and effective for patients with translocation‐related sarcoma (TRS) in Japan, its efficacy in other types of soft‐tissue sarcomas (STSs) remains unknown. This study retrospectively investigated its efficacy and safety through postmarketing surveillance of trabectedin in patients with unresectable and relapsed STS. Methods One hundred forty patients received intravenous trabectedin (1.2 mg/m2 on day 1 every 21 days) over the course of 24 hours. The primary endpoint was the efficacy and safety of trabectedin. Results Grade 3 or higher adverse events occurred in 100 patients (71%) and included hepatotoxicity (37.8%), neutropenia (32.8%), and rhabdomyolysis (3.6%). Patients at high risk for grade 3 or higher rhabdomyolysis (36%) were classified by height (≥170.3 cm) and age (≤32 years) through a classification and regression tree model (area under the curve, 0.9). The overall median progression‐free survival (PFS) was 3.7 months; with respect to the histological type, the median PFS was 17.4 months for myxoid liposarcoma, 4.9 months for leiomyosarcoma, 5.6 months for synovial sarcoma, and 3.7 months for dedifferentiated liposarcoma. Histological type (liposarcoma/leiomyosarcoma [L‐sarcoma] and TRS) and grade 3 neutropenia (but not grade 4) were associated with significantly improved PFS after trabectedin treatment (P = .003, P = .04, and P = .001). The median growth modulation index (GMI) was 0.91; 37 patients (36.7%) experienced a GMI > 1.33, and among patients with solitary fibrous tumors and undifferentiated pleomorphic sarcoma, 60% and 42.9%, respectively, had a GMI > 1.33. The median overall survival (OS) was 16.4 months. A GMI > 1.33 was associated with significantly improved OS (P = .0006). Conclusions Initial trabectedin at 1.2 mg/m2 has clinically meaningful benefits for patients with L‐sarcoma and certain histological subtypes of TRS.

show abstract

Section: Discussionmentioning

confidence: 51%

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

Kobayashi

Iwata

Wakamatsu

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…A total of 19 studies were included in the meta-analysis. Studies were excluded from the meta-analysis because the study did not include sufficient data to calculate odds ratios (n = 6) [19,26,30,36,41,43], did not dichotomize LSMM (n = 4) [32,33,38,40], or featured a toxicity endpoint that did not match with any other studies (n = 2) [6,42]. monotherapy which was used in the populations of more than one study.…”

Section: Search Resultsmentioning

confidence: 99%

“…The results of the QUIPS assessment of all included studies are summarized in Figure 2. Out of the 31 included studies, seven studies had a low risk of bias [6,16,19,24,25,34,38], 16 studies had a moderate risk of bias [5,7,8,[21][22][23]26,[28][29][30][31][32]35,37,43,44], and eight had a high risk of bias [20,27,33,36,[39][40][41][42]. The domains study participation, study confounding, and statistical analysis and reporting were most frequently assessed as having a high risk of bias.…”

Section: Study Quality Assessmentmentioning

confidence: 99%

The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis

Huiskamp

Chargi

Devriese

et al. 2020

JCM

View full text Add to dashboard Cite

Low skeletal muscle mass (LSMM) is increasingly recognized for its predictive value for adverse events in cancer patients. In specific, the predictive value of LSMM has been demonstrated for anti-cancer drug toxicity in a variety of cancer types and anti-cancer drugs. However, due to the limited sample size and study populations focused on a single cancer type, an overall predictive value of LSMM for anti-cancer drug toxicity remains unknown. Therefore, this review aims to provide a comprehensive overview of the predictive value of LSMM and perform a meta-analysis to analyse the overall effect. A systematic search was conducted of MEDLINE, Scopus, EMBASE, and Cochrane. Inclusion criteria were skeletal muscle mass (SMM) evaluated with computed tomography (CT) or magnetic resonance imaging (MRI), articles published in English, SMM studied in humans, SMM measurement normalized for height, and patients did not receive an intervention to treat or prevent LSMM. A meta-analysis was performed using a random-effects model and expressed in odds ratio (OR) with 95% confidence interval (CI). Heterogeneity was assessed using χ2 and I2 statistics. The search yielded 907 studies. 31 studies were included in the systematic review. Sample sizes ranged from 21 to 414 patients. The occurrence of LSMM ranged from 12.2% to 89.0%. The most frequently studied cancer types were oesophageal, renal, colorectal, breast, and head and neck cancer. Patients with LSMM had a higher risk of severe toxicity (OR 4.08; 95% CI 2.48–6.70; p < 0.001) and dose-limiting toxicity (OR 2.24; 95% CI 1.28–3.92; p < 0.001) compared to patients without LSMM. To conclude, the predictive value of LSMM for anti-cancer drug toxicity can be observed across cancer types. This information increases the need for further research into interventions that could treat LSMM as well as the possibility to adapt treatment regimens based on the presence of LSMM.

show abstract

“…With the advent of granulocyte-colony stimulating factor (G-CSF) preparations, progress has been made in the treatment and prevention of FN, but it is still a complication requiring clinical attention (Petru et al, 2015). Pretreatment weight loss (underweight) and hypoalbuminemia have been reported to be two of the important risk factors of the development of FN in several hematological and nonhematological malignant diseases (Aoyagi, Morii, Tajima, Yoshiyama, & Ichimura, 2015;Kobayashi et al, 2019;Lapointe et al, 2005;Pettengell et al, 2009;Schwenkglenks, Bendall, Pfeil, Szabo, & Pettengell, 2013). Studies…”

Section: Introductionmentioning

confidence: 99%

Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients

Kayauchi

Nakagawa

Oteki

et al. 2020

Asian Pac Isl Nurs Js

View full text Add to dashboard Cite

Although advances have been made in the treatment and prevention of febrile neutropenia (FN) in cancer patients treated with chemotherapy, it is still a complication that requires clinical attention. Impaired nutritional status in patients who develop FN can affect the continuation of cancer treatment, but it has not been investigated. We conducted a retrospective longitudinal study in order to clarify (1) if body weight and serum albumin levels change in lung cancer patients who do and do not develop FN, and (2) if these indicators are more likely to worsen in patients with FN than in patients without FN. Patients undergoing cytotoxic chemotherapy between January 2011 and June 2020 were consecutively included in the study. Changes in body weight and serum albumin levels were investigated in a case–control study of patients with FN, and control patients without FN who were matched by age, gender, histopathology, and stage of lung cancer, at a ratio of 1:2. During the study period, 226 patients received cytotoxic chemotherapy. Among those, 33 (14.6%) patients developed FN during the first course of cytotoxic chemotherapy. We found a more pronounced decrease in both body weight and serum albumin level at four weeks after the initiation of chemotherapy in FN patients. In order to safely administer effective chemotherapy, medical staff need to pay close attention to the nutritional status of patients receiving chemotherapy.

show abstract

Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma

Cited by 11 publications

References 36 publications

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis

Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients

Contact Info

Product

Resources

About